UNRESECTABLE DEDIFFERENTIATED LIPOSARCOMA
Clinical trials for UNRESECTABLE DEDIFFERENTIATED LIPOSARCOMA explained in plain language.
Never miss a new study
Get alerted when new UNRESECTABLE DEDIFFERENTIATED LIPOSARCOMA trials appear
Sign up with your email to follow new studies for UNRESECTABLE DEDIFFERENTIATED LIPOSARCOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo therapy aims to shrink Hard-to-Treat sarcomas
Disease control OngoingThis study compares two treatments for advanced dedifferentiated liposarcoma, a rare cancer. One group gets palbociclib alone, the other gets palbociclib plus cemiplimab. The goal is to see if the combination helps stop cancer growth better than the single drug. About 77 adults w…
Matched conditions: UNRESECTABLE DEDIFFERENTIATED LIPOSARCOMA
Phase: PHASE2 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated May 22, 2026 14:02 UTC
-
New drug duo targets hard-to-treat sarcoma
Disease control OngoingThis study tests whether combining two drugs (etrumadenant and zimberelimab) can shrink tumors or slow the disease in people with advanced dedifferentiated liposarcoma that has returned, spread, or cannot be removed by surgery. About 16 adults with this rare soft-tissue cancer wi…
Matched conditions: UNRESECTABLE DEDIFFERENTIATED LIPOSARCOMA
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 22, 2026 13:53 UTC